Vaccinex, Inc. And OPi, SAS Announce Antibody Collaboration
10/19/2005 5:08:56 PM
Vaccinex, Inc. and OPi announced today a strategic collaboration to discover and develop novel monoclonal antibodies for the treatment of certain rare hematological diseases. Vaccinex will use its proprietary antibody discovery technologies to create fully human antibodies with the same specificity and function as OPi’s panel of existing mouse monoclonal antibodies, some of which have already shown promising results in human trials. Under the agreement, Vaccinex will have the opportunity to participate as a co-development partner in certain markets.
comments powered by